Price vs. performance: CAR T-cells
Novel agents in CLL: the importance of affordability
Can we afford to have CLL patients on a therapy for the rest of their lives?
John Gribben et al.
Enhancing autologous cellular therapy with ibrutinib in CLL patients
Iris de Weerdt
Drug combinations in CLL: ibrutinib, idelalisib and more